Cargando…
Corrigendum: Targeting myeloid checkpoint molecules in combination with antibody therapy: A novel anti-cancer strategy with IgA antibodies?
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9514090/ https://www.ncbi.nlm.nih.gov/pubmed/36177025 http://dx.doi.org/10.3389/fimmu.2022.1017924 |
| _version_ | 1784798203211677696 |
|---|---|
| author | Chan, Chilam Lustig, Marta Baumann, Niklas Valerius, Thomas van Tetering, Geert Leusen, Jeanette H. W. |
| author_facet | Chan, Chilam Lustig, Marta Baumann, Niklas Valerius, Thomas van Tetering, Geert Leusen, Jeanette H. W. |
| author_sort | Chan, Chilam |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9514090 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Frontiers Media S.A. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-95140902022-09-28 Corrigendum: Targeting myeloid checkpoint molecules in combination with antibody therapy: A novel anti-cancer strategy with IgA antibodies? Chan, Chilam Lustig, Marta Baumann, Niklas Valerius, Thomas van Tetering, Geert Leusen, Jeanette H. W. Front Immunol Immunology Frontiers Media S.A. 2022-09-13 /pmc/articles/PMC9514090/ /pubmed/36177025 http://dx.doi.org/10.3389/fimmu.2022.1017924 Text en Copyright © 2022 Chan, Lustig, Baumann, Valerius, van Tetering and Leusen https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| spellingShingle | Immunology Chan, Chilam Lustig, Marta Baumann, Niklas Valerius, Thomas van Tetering, Geert Leusen, Jeanette H. W. Corrigendum: Targeting myeloid checkpoint molecules in combination with antibody therapy: A novel anti-cancer strategy with IgA antibodies? |
| title | Corrigendum: Targeting myeloid checkpoint molecules in combination with antibody therapy: A novel anti-cancer strategy with IgA antibodies? |
| title_full | Corrigendum: Targeting myeloid checkpoint molecules in combination with antibody therapy: A novel anti-cancer strategy with IgA antibodies? |
| title_fullStr | Corrigendum: Targeting myeloid checkpoint molecules in combination with antibody therapy: A novel anti-cancer strategy with IgA antibodies? |
| title_full_unstemmed | Corrigendum: Targeting myeloid checkpoint molecules in combination with antibody therapy: A novel anti-cancer strategy with IgA antibodies? |
| title_short | Corrigendum: Targeting myeloid checkpoint molecules in combination with antibody therapy: A novel anti-cancer strategy with IgA antibodies? |
| title_sort | corrigendum: targeting myeloid checkpoint molecules in combination with antibody therapy: a novel anti-cancer strategy with iga antibodies? |
| topic | Immunology |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9514090/ https://www.ncbi.nlm.nih.gov/pubmed/36177025 http://dx.doi.org/10.3389/fimmu.2022.1017924 |
| work_keys_str_mv | AT chanchilam corrigendumtargetingmyeloidcheckpointmoleculesincombinationwithantibodytherapyanovelanticancerstrategywithigaantibodies AT lustigmarta corrigendumtargetingmyeloidcheckpointmoleculesincombinationwithantibodytherapyanovelanticancerstrategywithigaantibodies AT baumannniklas corrigendumtargetingmyeloidcheckpointmoleculesincombinationwithantibodytherapyanovelanticancerstrategywithigaantibodies AT valeriusthomas corrigendumtargetingmyeloidcheckpointmoleculesincombinationwithantibodytherapyanovelanticancerstrategywithigaantibodies AT vanteteringgeert corrigendumtargetingmyeloidcheckpointmoleculesincombinationwithantibodytherapyanovelanticancerstrategywithigaantibodies AT leusenjeanettehw corrigendumtargetingmyeloidcheckpointmoleculesincombinationwithantibodytherapyanovelanticancerstrategywithigaantibodies |